Developing Markets for Pharmaceuticals, 2006-2011

The purpose of this visiongain report is to examine the prospects for the growth of pharmaceutical revenues in the developing economies of Asia, Latin America and Eastern/Central Europe at both regional and national level.

The growth of pharmaceutical markets in the developing nations has the potential to offset serious problems currently experienced by the global industry. The principal challenge is slow growth in North America, Western Europe and Japan.

In contrast, visiongain predicts that all the leading developing markets will exhibit strong growth from 2006-2011. Rapid economic growth and large, under-served populations will drive that expansion. There will be significant growth in sales of both branded and generic drugs through increasing demand from both public and private healthcare sectors.

Developing Markets for Pharmaceuticals, 2006-2011, examines developing pharmaceutical markets critically through comprehensive research and analysis. Visiongain applied techniques such as financial forecasting, SWOT analyses and discussion of qualitative factors. Societal, political, economic and commercial issues are covered. The result is a comprehensive market-based report with detailed analysis and informed opinion.

In particular, Developing Markets for Pharmaceuticals, 2006-2011, concentrates on the following themes:

> A forecast of the global pharmaceutical market from 2006-2011, with key issues discussed

> Forecasts of sales revenues and growth rates for leading developing markets in Asia, Latin America and > Eastern/Central Europe from 2006-2011

> Drivers and opportunities in those markets

> Restraints and threats in those markets

> Discussion of key players and important therapeutic areas

> Discussion of relevant regulatory, societal and economic issues

Why you should buy this report:

> To receive a comprehensive analysis of the prospects for developing regional and national markets for pharmaceuticals in Asia, Latin America and Central/Eastern Europe from 2006-2011

> To discover predicted revenues, growth rates and other key metrics for developing markets from 2006-2011

> To determine the forces that influence pharmaceutical sales in the developing markets:

> Competitive characteristics of the market

> Regulatory, technological, societal and political issues

> Drivers and restraints

> Strengths, weaknesses, opportunities and threats

The dominant pharmaceutical markets of North America, Western Europe and Japan currently account for approximately 85% of revenues for prescription drugs. However, there is concern about the relatively low growth of those established markets in recent years. Consequently, international pharmaceutical companies are very interested in raising their profile in the developing markets of Asia, Latin America and Eastern/Central Europe.

Growth of the pharmaceutical markets in developing nations will clearly surpass that of the established markets. That situation will provide one of the greatest opportunities currently available to the international pharmaceutical industry. Many developing countries have strongly growing economies; that factor constitutes a driving force in the reform and broadening of healthcare systems. Improvements in both the quality and reach of these healthcare provisions will drive the sales of branded and generic products. Private healthcare will undergo similar developments.

Manufacturers of pharmaceuticals are currently working hard to address unmet healthcare needs in developing countries. By doing so, they are making better treatments available to millions of patients and improving the overall performance of their companies.

Lead Analyst: Dr Gordon Low Publication Date: 14/09/06 Pages: 207

Single user licence: The Report is delivered via an on-line reading room. One use access only, the report is in Flash format in a printable format.

Department: Report is delivered via an on line reading room. Five user access only, the report is in Flash format in a printable format.

Company/site wide licence: The report is delivered in email format as a PDF document with no locking system attached. The report can be loaded onto the company's intranet site.
Table of Contents

Price
Single User Licence $2998.00
Department Licence 5 Users $5998.00
Company-wide Intranet Licence $9998.00